Short answer
Biogen (BIIB) filed an 8-K current report with the SEC on April 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 preliminary charge: approximately $34 million pre-tax for acquired R&D, upfront and milestone expenses.
Biogen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 preliminary charge: approximately $34 million pre-tax for acquired R&D, upfront and milestone expenses
- Estimated GAAP and non-GAAP EPS impact: approximately $0.19 per diluted share
- Charge reflects collaboration and licensing activity, signaling investment in Biogen’s pipeline and potential near-term earnings pressure
- Results for quarter ended March 31, 2026 remain unaudited and subject to closing adjustments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biogen 8-K filings
Get the next BIIB 8-K as it lands
Follow BIIB for push alerts, or ask the research agent what this filing means.